Results 1 to 10 of about 5,996 (130)

Immunogenicity of a Recombinant Zoster Vaccine (gE/BFA01) in Mice [PDF]

Viruses
Varicella-zoster virus (VZV) is a human neurotropic herpesvirus. The primary infection with VZV causes chickenpox and establishes latency in sensory and dorsal root ganglia.
Yaru Quan, Shiqiang Luo, Shuang Wu, Kaiqin Wang, Lixing Hu, Yihuan Hao, Kangwei Xu, Yong Liu   +7 more
doaj   +2 more sources

Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older. [PDF]

Alzheimers Dement
Abstract INTRODUCTION Herpes zoster vaccines may lower the risk of dementia onset. We evaluated new‐onset dementia among US Medicare beneficiaries ≥65 years old following recombinant zoster vaccination (RZV). METHODS We matched one RZV‐exposed to two RZV‐unvaccinated on age, sex, and race/ethnicity. Individuals were ≥65 years old on the RZV dose 2 date
Dos Reis S, Tran P, Mohanty K, Amill-Rosario A, Johnson A, Ryan K, Alsdurf H, Oraichi D, Yun H.   +8 more
europepmc   +2 more sources

Recombinant zoster vaccine induces superior immunogenicity compared with live varicella vaccine in allogeneic haematopoietic stem cell transplantation recipients. [PDF]

Br J Haematol
British Journal of Haematology, Volume 208, Issue 6, Page 2288-2292, June 2026.
Ono T, Okada T, Ikeda R, Yamashita M, Koyauchi K, Takagi F, Adachi M, Takemura T, Mitsui K, Nagata Y.   +9 more
europepmc   +2 more sources

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review

Human Vaccines & Immunotherapeutics, 2023
The objective of this study was to critically review the cost-effectiveness (CE) of the recombinant zoster vaccine (RZV) against herpes zoster (HZ). A literature review was conducted in PubMed, Embase, and Cochrane between January 1, 2017, and February ...
Nikolaos Giannelos, Cheryl Ng, Desmond Curran   +2 more
doaj   +2 more sources

Herpes zoster ophthalmicus following recombinant zoster vaccine: A case report and brief literature review [PDF]

IDCases
Purpose: Immunizations have long been pivotal in preventing diseases like HZ (herpes zoster), caused by VZV (varicella zoster virus). This study aims to evaluate the efficacy and safety of the RZV (recombinant zoster vaccine) compared to the ZVL (zoster ...
Joshua M. Garcia, Ramez I. Haddadin
doaj   +2 more sources

The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide [PDF]

Infectious Diseases and Therapy
Introduction Herpes zoster (HZ, Shingles) is a vaccine-preventable viral disease impacting patients’ quality of life owing to pain and rash. An estimated 15 million HZ cases occur annually in individuals aged ≥ 50 years worldwide.
Nikolaos Giannelos, Desmond Curran, Sean Matthews, Justin Carrico, Anthony L. Cunningham   +4 more
doaj   +2 more sources

Lichen planus following recombinant zoster vaccine [PDF]

JAAD Case Reports
Charli C. Gruen, 2d Lt, USAF, BS, Bianca N. Coffel, Capt, USAF, MD, Paul Hahn, Lt Col, USA, MD   +2 more
doaj   +2 more sources

Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines

Viruses, 2022
Infection with varicella zoster virus typically occurs in children and it can cause primary varicella infection or “chickenpox”, or it can reactivate later in life and cause herpes zoster or “shingles”.
Yasmin Marra, Fawziah Lalji
doaj   +1 more source

Recombinant zoster vaccine and the risk of dementia [PDF]

Vaccine
Benjamin F Arnold, Nisha R Acharya
exaly   +2 more sources

Herpes zoster vaccination. An update

Przegląd Dermatologiczny, 2022
Herpes zoster/shingles is a cutaneous condition caused by the reactivation of varicella zoster virus. The condition mostly occurs when the cell mediated immunity towards varicella zoster virus, which was developed during the varicella zoster virus ...
Khairuddin Djawad, Safruddin Amin, Anni Adriani, Widyawati Djamaluddin, Dirmawati Kadir, Sri Muchtar   +5 more
doaj   +1 more source